Department of Medicine, Section of Dermatology and Venereology, University of Verona , Verona, Italy.
Expert Opin Biol Ther. 2020 Oct;20(10):1175-1186. doi: 10.1080/14712598.2020.1776256. Epub 2020 Jun 16.
A number of highly selective biologic therapies that target specific immunological pathways of psoriasis have emerged, including molecules that target interleukin (IL)-17. IL-17 has been identified as a key effector pathogenic cytokine in psoriasis, and validated as a highly effective therapeutic target for the treatment of plaque psoriasis.
This review examines the therapeutic efficacy and safety of IL-17 inhibitors in plaque psoriasis and provides an overview of the efficacy and safety data of brodalumab compared with other IL-17 inhibitors.
In the real world, the treatment of psoriasis has been revolutionized by the new class of drugs belonging to IL-17 inhibitors, with secukinumab, ixekizumab, and brodalumab currently licensed and approved for the treatment of moderate-to-severe plaque psoriasis. With its distinct mechanism of action, brodalumab may offer a unique advantage over other IL-17 inhibitors due to its rapid onset of action, achievement of complete skin clearance in a high proportion of patients, and its overall favorable safety profile. Importantly, treatment with systemic biologic drugs should be established early on in the course of the disease in order to prevent comorbidities and to allow patients to achieve a stable and persistent remission.
已经出现了许多针对银屑病特定免疫途径的高度选择性生物疗法，包括针对白细胞介素（IL）-17 的分子。IL-17 已被确定为银屑病中的关键效应致病细胞因子，并被验证为治疗斑块型银屑病的有效治疗靶点。
本综述检查了 IL-17 抑制剂在斑块型银屑病中的治疗效果和安全性，并概述了与其他 IL-17 抑制剂相比，布罗达卢单抗的疗效和安全性数据。
在现实世界中，属于 IL-17 抑制剂的新型药物彻底改变了银屑病的治疗方法，目前已批准司库奇尤单抗、依奇珠单抗和布罗达卢单抗用于治疗中重度斑块型银屑病。由于其独特的作用机制，布罗达卢单抗可能比其他 IL-17 抑制剂具有独特的优势，因为它具有快速起效、使大多数患者实现完全皮肤清除以及总体良好的安全性特征。重要的是，为了预防并发症并使患者达到稳定和持续的缓解，应在疾病早期开始使用全身性生物药物治疗。
